? Abramson Cancer Center BioRepository (ABR) The Abramson Cancer Center BioRepository (ABR) is a shared core laboratory comprised of four integrated components that together enable the collection of tumor and normal tissue samples from surgical resections and radiology guided biopsy (supporting clinical trials), blood collections (buffy coats, serum and plasma), and liquid biopsy (ctDNA, CTC, soluble proteins and extra-cellular vesicles). This integrated Shared Resource leverages uniformity of quality across a breadth of biosamples and enhanced efficiencies gained through use of a universal consent. The tumor tissue, blood collection and liquid biopsy material collections are supported by a new prospective universal consent allowing for collection of blood and tissue (at time of surgery), patient re-contact, ?omics? study of the collected biosamples, and linkage to electronic health records for outcome- related translational research. Biosample inventory data are managed through Open Specimen, a commercial biosample database on the tissue side, and Pumpkin, a home-grown system for blood sample processing ? both well-suited to handle large volume sample collections and archiving. Penn Medicine has a centralized informatics infrastructure (PennOmics v2) composed of an enterprise DataLake that combines EHR data, tumor registry data, and genomic data (germline and somatic studies) that links to stored biosample inventories across our biosample database (Open Specimen and Pumpkin) that allows for cohort exploration and requesting biosamples from these cohorts. Biosamples are stored in two new freezer farms recently constructed at the Perelman School of Medicine in either -80 freezers (buffy coats, plasma and serum) or LN2 vapor (tissue or viable cells). Both freezer farms have completely redundant air conditioning, electric and central monitoring resources including remote monitoring and alarms with O2 security sensors to support LN2 vapor storage. ABR is tightly coupled with a larger institutional biosample repository (Penn Medicine Biobank) which has grown to >60K patient blood samples, including whole exome sequencing and genotyping on >15K of these patients. The Penn Medicine Biobank is a broad effort across Penn Medicine that seeks to collect blood and tissues across a wide range of both normal patients as well as patients with a variety of diseases. The ABR Shared Resource is directed by Dr. Michael Feldman, who has been leading the tumor tissue and blood repository since its inception in 2005. Ms. Joellen Weaver, Technical Director, has worked in biobanking for 20 years. ACC members accounted for 43 of 62 investigators (69%) using this Shared Resource during the most recent reporting period (07/01/18-06/30/19). ABR has supported high-impact research, e.g. changing the fundamental understanding of immune suppression in tumors via PDL1-carrying exosomes (Chen et al., Nature, 2018). ABR facilitates access to a wide variety and number of biospecimens for ACC members across the basic, clinical, and population science Programs, addressing the changing scientific needs of ACC membership and increased research demand for tissue and blood products.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088758
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5

Showing the most recent 10 out of 1047 publications